Oral Session 1-15C Multiple Myeloma: Clinical (1)

[OS1-15C-1] Comparative effectiveness of frontline treatments for transplant-ineligible NDMM patients

Alison Keetley¹, Thierry Facon², Jesus San-Miguel³, Saad Z. Usmani⁴, Meletios A. Dimopoulos⁵, Shaji Kumar⁶, Maria-Victoria Mateos⁷, Michele Cavo⁸, Bart Heeg⁹, Sophie van Beekhuizen⁹, Marta Pisini¹⁰, Sandhya Nair¹¹, Annette Lam¹², Mary Slavcev¹², Jianming He¹² (1.Janssen Asia Pacific Pte Ltd, Singapore, Republic of Singapore, 2.Hôpital Claude Huriez, CHRU Lille, Lille, France Metropolitan, 3.Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain, 4.Levine Cancer Institute/Atrium Health, Charlotte, NC, United States of America, 5.National and Kapodistrian University of Athens, Athens, Hellenic Republic, 6.Department of Hematology, Mayo Clinic Rochester, Rochester, MN, United States of America, 7.University Hospital of Salamanca/IBSAL, Salamanca, Spain, 8.Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italian Republic, 9.Ingress Health, Rotterdam, Kingdom of the Netherlands, 10.Janssen EMEA, Beerse, Kingdom of Belgium, 11.Janssen Pharmaceutica NV, Beerse, Kingdom of Belgium, 12.Janssen Global Services, Raritan, NJ, United States of America)